Testing effectiveness (Phase 2)Looking for participantsNCT07025889What this trial is testingIBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerWho this might be right forGastric Cancer Ruijin Hospital 55
Not applicableLooking for participantsNCT06846996What this trial is testingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaWho this might be right forHER2-positive Gastric CancerHER2-positive Gastroesophageal Junction Daiichi Sankyo 260
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06374888What this trial is testingNilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain MetastasesWho this might be right forHer2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis Convalife (Shanghai) Co., Ltd. 28
Early research (Phase 1)Not Yet RecruitingNCT07581574What this trial is testingNeoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ AdenocarcinomaWho this might be right forGastric or Gastroesophageal Junction Adenocarcinoma The First Affiliated Hospital with Nanjing Medical University 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384What this trial is testingAdjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionWho this might be right forEsophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more Brown University 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT06681298What this trial is testingA Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With TrastuzumabWho this might be right forAdenocarcinoma of the Esophagogastric JunctionPerioperative Period xiaohua li 36
Testing effectiveness (Phase 2)Study completedNCT01472029What this trial is testingExplorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or StomachWho this might be right forAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach AIO-Studien-gGmbH 53
Large-scale testing (Phase 3)Study completedNCT00680901What this trial is testingLOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibWho this might be right forNeoplasms, Gastrointestinal Tract Novartis Pharmaceuticals 545
Early research (Phase 1)Ended earlyNCT01705340What this trial is testingAkt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryWho this might be right forAdenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more National Cancer Institute (NCI) 60
Post-approval studies (Phase 4)Not Yet RecruitingNCT07829757What this trial is testingZolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric CancerWho this might be right forLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT07431281What this trial is testingSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Who this might be right forGastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer AstraZeneca 2,130
Large-scale testing (Phase 3)Active Not RecruitingNCT06238843What this trial is testingA Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)Who this might be right forUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Innovent Biologics (Suzhou) Co. Ltd. 464
Testing effectiveness (Phase 2)Looking for participantsNCT07334431What this trial is testingFruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric CancerWho this might be right forGastric AdenocarcinomaGastric (Stomach) CancerGEJ Adenocarcinoma+3 more Henan Cancer Hospital 45
Early research (Phase 1)Study completedNCT01576666What this trial is testingPhase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsWho this might be right forDose EscalationSafetyPreliminary Efficacy+9 more Novartis Pharmaceuticals 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05002127What this trial is testingEvorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Who this might be right forGastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma ALX Oncology Inc. 127
Testing effectiveness (Phase 2)Looking for participantsNCT07327229What this trial is testingA Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaWho this might be right forUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Antengene Biologics Limited 132
Not applicableStudy completedNCT01220934What this trial is testingAn Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric CancerWho this might be right forGastric Cancer Hoffmann-La Roche 443
Testing effectiveness (Phase 2)Active Not RecruitingNCT05034887What this trial is testingPhase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction AdenocarcinomaWho this might be right forGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma National Cancer Center Hospital East 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716111What this trial is testingNeoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ AdenocarcinomaWho this might be right forGastric or Gastroesophageal Junction Adenocarcinoma The First Affiliated Hospital with Nanjing Medical University 24
Not applicableActive Not RecruitingNCT05993234What this trial is testingTrastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)Who this might be right forHER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 257